-
Mashup Score: 3Targeting IL-12 Safely With Intraperitoneal Therapy Represents Key Step Forward in Ovarian Cancer - 26 day(s) ago
Premal Thaker, MD, MS, discusses considerations when targeting IL-12 in ovarian cancer and how IMNN-001 has shown the potential to do so.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3Targeting IL-12 Safely With Intraperitoneal Therapy Represents Key Step Forward in Ovarian Cancer - 27 day(s) ago
Premal Thaker, MD, MS, discusses considerations when targeting IL-12 in ovarian cancer and how IMNN-001 has shown the potential to do so.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Targeting IL-12 Safely With Intraperitoneal Therapy Represents Key Step Forward in Ovarian Cancer @sitemancenter #oncology #ovariancancer https://t.co/TovwbWdlDt
-
-
Mashup Score: 2Targeting IL-12 Safely With Intraperitoneal Therapy Represents Key Step Forward in Ovarian Cancer - 1 month(s) ago
Premal Thaker, MD, MS, discusses considerations when targeting IL-12 in ovarian cancer and how IMNN-001 has shown the potential to do so.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Targeting IL-12 Safely With Intraperitoneal Therapy Represents Key Step Forward in Ovarian Cancer @sitemancenter #oncology #ovariancancer https://t.co/TovwbWdlDt
-
-
Mashup Score: 1FDA Approval Sought for Avutometinib Plus Defactinib in Recurrent KRAS+ Low-Grade Serous Ovarian Cancer - 2 month(s) ago
A rolling NDA seeking the approval of avutometinib plus defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer has been submitted to the FDA.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Approval Sought for Avutometinib Plus Defactinib in Recurrent KRAS+ Low-Grade Serous Ovarian Cancer. #oncology #ovariancancer https://t.co/ZDAwZmbjnw
-
-
Mashup Score: 1FDA Approval Sought for Avutometinib Plus Defactinib in Recurrent KRAS+ Low-Grade Serous Ovarian Cancer - 2 month(s) ago
A rolling NDA seeking the approval of avutometinib plus defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer has been submitted to the FDA.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Approval Sought for Avutometinib Plus Defactinib in Recurrent KRAS+ Low-Grade Serous Ovarian Cancer. #oncology #ovariancancer https://t.co/ZDAwZmbjnw
-
-
Mashup Score: 1FDA Approval Sought for Avutometinib Plus Defactinib in Recurrent KRAS+ Low-Grade Serous Ovarian Cancer - 2 month(s) ago
A rolling NDA seeking the approval of avutometinib plus defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer has been submitted to the FDA.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Approval Sought for Avutometinib Plus Defactinib in Recurrent KRAS+ Low-Grade Serous Ovarian Cancer. #oncology #ovariancancer https://t.co/ZDAwZmbjnw
-
-
Mashup Score: 1IMNN-01 Plus Perioperative Chemo Improves OS in Newly Diagnosed, Advanced Ovarian Cancer - 5 month(s) ago
IMNN-001 plus perioperative chemotherapy improved overall survival in newly diagnosed, advanced ovarian cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
IMNN-01 Plus Perioperative Chemo Improves OS in Newly Diagnosed, Advanced Ovarian Cancer. #oncology #ovariancancer https://t.co/jIli0ycEZq
-
-
Mashup Score: 1Trabectedin Monotherapy Does Not Improve OS vs Chemotherapy in BRCA-Mutated Recurrent Ovarian Cancer - 11 month(s) ago
Trabectedin did not offer a survival benefit vs chemotherapy in recurrent ovarian cancer with BRCA-mutated and/or BRCAness phenotype.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Trabectedin Monotherapy Does Not Improve OS vs Chemotherapy in BRCA-Mutated Recurrent Ovarian Cancer. #oncology #ovariancancer https://t.co/FtogChCr3I
-
-
Mashup Score: 1Trabectedin Monotherapy Does Not Improve OS vs Chemotherapy in BRCA-Mutated Recurrent Ovarian Cancer - 11 month(s) ago
Trabectedin did not offer a survival benefit vs chemotherapy in recurrent ovarian cancer with BRCA-mutated and/or BRCAness phenotype.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Trabectedin Monotherapy Does Not Improve OS vs Chemotherapy in BRCA-Mutated Recurrent Ovarian Cancer. #oncology #ovariancancer https://t.co/FtogChCr3I
-
Targeting IL-12 Safely With Intraperitoneal Therapy Represents Key Step Forward in Ovarian Cancer @sitemancenter #oncology #ovariancancer https://t.co/TovwbWdlDt